FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766489098> ?p ?o ?g. }

• W2766489098 endingPage "e8039" @default.
• W2766489098 startingPage "e8039" @default.
• W2766489098 abstract "Invasive pulmonary aspergillosis is associated with significant morbidity and mortality in patients with liver failure. Voriconazole (VRCZ) is recommended as a primary therapeutic agent for the treatment of invasive aspergillosis and metabolized in the liver. Now, data are still lacking on the safety and appropriate dosage of VRCZ in patients with liver failure. Here, we report a representative case of invasive pulmonary fungal infection in a patient with liver failure who was treated with low-dose VRCZ.A 21-year-old man, presented with subacute liver failure caused suspected by viral infection, was admitted on June 22, 2014. Liver function was not improved by the treatment of gancicolovir and methylprednisolone. The patient presented with fever, cough, and hyperpyrexia on July 14. Laboratory tests revealed raised neutrophil percentage (82.1%, normal range [NR] 50-70), international normalized ratio (INR) (2.32, NR 0.8-1.2) and levels of serum lactic acid (4.308 mmol/L, NR 0.6-2.2), alanine transaminase (165 U/L,NR 0-40), aspartate transaminase (99 U/L, NR 8-40), and total bilirubin (654 mmol/L, NR 3.4-20.5). Furthermore, CD4+ T cell, CD8+T cell, and B cell count were low (169, 221, and l8/mL, respectively). Sputum smear microscopy for bacteria was negative, but the direct observation for fungal elements was positive. Thoracic CT scan revealed bilateral pulmonary high-density shadow. Sputum cultures were positive 2 days later with the presence of Aspergillus fumigatus.Therefore, this patient diagnosed with suspected pulmonary a spergillosis.VRCZ was used on July 15th and its dosage was 400 mg twice on day 1 followed by a maintenance dose of 100 mg twice daily according to drug usage instruction. However, some side effects, such as tremors, lips twitching, and hair loss, occurred. Plasma VRCZ trough concentration was 8.1 mg/mL which was much higher than the recommend level. Therefore, VRCZ dosage was adjusted according to its plasma concentration. VRCZ plasma concentration fluctuated between 2.5 to 4.7 mg/mL when its dosage was 100 mg once daily and side effects disappeared.VRCZ was administered for 2 months. This patient's symptoms and liver function were improved. A follow-up CT scan performed at the end of VRCZ therapy indicated that the high-density shadow had diminished.This case demonstrated that low-dose VRCZ (maintenance dose, 100 mg/day) can achieve effective plasma concentration and reduce side effects without liver damage. We believe that VRCZ is safe to be administered in patients with liver failure, but its plasma concentration should be carefully monitored." @default.
• W2766489098 created "2017-11-10" @default.
• W2766489098 creator A5004349988 @default.
• W2766489098 creator A5004870976 @default.
• W2766489098 creator A5009016909 @default.
• W2766489098 creator A5019373008 @default.
• W2766489098 creator A5023889709 @default.
• W2766489098 creator A5037216734 @default.
• W2766489098 creator A5049920455 @default.
• W2766489098 creator A5064304964 @default.
• W2766489098 date "2017-10-01" @default.
• W2766489098 modified "2023-09-27" @default.
• W2766489098 title "Significance of monitoring plasma concentration of voriconazole in a patient with liver failure" @default.
• W2766489098 cites W1496743393 @default.
• W2766489098 cites W1834911564 @default.
• W2766489098 cites W1974054133 @default.
• W2766489098 cites W1985282417 @default.
• W2766489098 cites W1992995027 @default.
• W2766489098 cites W1994536693 @default.
• W2766489098 cites W2000873597 @default.
• W2766489098 cites W2007802356 @default.
• W2766489098 cites W2012789840 @default.
• W2766489098 cites W2014557179 @default.
• W2766489098 cites W2015870178 @default.
• W2766489098 cites W2036323185 @default.
• W2766489098 cites W2051816101 @default.
• W2766489098 cites W2060356713 @default.
• W2766489098 cites W2062355274 @default.
• W2766489098 cites W2065343663 @default.
• W2766489098 cites W2095445385 @default.
• W2766489098 cites W2097124667 @default.
• W2766489098 cites W2123134253 @default.
• W2766489098 cites W2139365607 @default.
• W2766489098 cites W2144766297 @default.
• W2766489098 cites W2148094064 @default.
• W2766489098 cites W2148605276 @default.
• W2766489098 cites W2164996340 @default.
• W2766489098 cites W2258984734 @default.
• W2766489098 cites W2299734421 @default.
• W2766489098 cites W2317720949 @default.
• W2766489098 cites W2326396770 @default.
• W2766489098 cites W2470332163 @default.
• W2766489098 doi "https://doi.org/10.1097/md.0000000000008039" @default.
• W2766489098 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5662357" @default.
• W2766489098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29049191" @default.
• W2766489098 hasPublicationYear "2017" @default.
• W2766489098 type Work @default.
• W2766489098 sameAs 2766489098 @default.
• W2766489098 citedByCount "6" @default.
• W2766489098 countsByYear W27664890982018 @default.
• W2766489098 countsByYear W27664890982019 @default.
• W2766489098 countsByYear W27664890982022 @default.
• W2766489098 countsByYear W27664890982023 @default.
• W2766489098 crossrefType "journal-article" @default.
• W2766489098 hasAuthorship W2766489098A5004349988 @default.
• W2766489098 hasAuthorship W2766489098A5004870976 @default.
• W2766489098 hasAuthorship W2766489098A5009016909 @default.
• W2766489098 hasAuthorship W2766489098A5019373008 @default.
• W2766489098 hasAuthorship W2766489098A5023889709 @default.
• W2766489098 hasAuthorship W2766489098A5037216734 @default.
• W2766489098 hasAuthorship W2766489098A5049920455 @default.
• W2766489098 hasAuthorship W2766489098A5064304964 @default.
• W2766489098 hasBestOaLocation W27664890981 @default.
• W2766489098 hasConcept C126322002 @default.
• W2766489098 hasConcept C141071460 @default.
• W2766489098 hasConcept C142724271 @default.
• W2766489098 hasConcept C16005928 @default.
• W2766489098 hasConcept C160160445 @default.
• W2766489098 hasConcept C181199279 @default.
• W2766489098 hasConcept C185592680 @default.
• W2766489098 hasConcept C203014093 @default.
• W2766489098 hasConcept C2776301714 @default.
• W2766489098 hasConcept C2777714996 @default.
• W2766489098 hasConcept C2778606649 @default.
• W2766489098 hasConcept C2779548794 @default.
• W2766489098 hasConcept C2779609443 @default.
• W2766489098 hasConcept C2779679107 @default.
• W2766489098 hasConcept C2779787849 @default.
• W2766489098 hasConcept C2780690907 @default.
• W2766489098 hasConcept C2781069245 @default.
• W2766489098 hasConcept C2911091166 @default.
• W2766489098 hasConcept C2992208098 @default.
• W2766489098 hasConcept C512861765 @default.
• W2766489098 hasConcept C55493867 @default.
• W2766489098 hasConcept C71924100 @default.
• W2766489098 hasConcept C75603125 @default.
• W2766489098 hasConcept C90924648 @default.
• W2766489098 hasConceptScore W2766489098C126322002 @default.
• W2766489098 hasConceptScore W2766489098C141071460 @default.
• W2766489098 hasConceptScore W2766489098C142724271 @default.
• W2766489098 hasConceptScore W2766489098C16005928 @default.
• W2766489098 hasConceptScore W2766489098C160160445 @default.
• W2766489098 hasConceptScore W2766489098C181199279 @default.
• W2766489098 hasConceptScore W2766489098C185592680 @default.
• W2766489098 hasConceptScore W2766489098C203014093 @default.
• W2766489098 hasConceptScore W2766489098C2776301714 @default.
• W2766489098 hasConceptScore W2766489098C2777714996 @default.
• W2766489098 hasConceptScore W2766489098C2778606649 @default.

• next